Literature DB >> 33613512

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.

Xidan Gao1, Hongshu Sui1, Shang Zhao2, Xingmei Gao3, Yanping Su1, Peng Qu4.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that accumulate in tumor-bearing hosts to reduce T cells activity and promote tumor immune escape in the tumor microenvironment (TME). The immune system in the TME can be stimulated to elicit an anti-tumor immune response through immunotherapy. The main theory of immunotherapy resides on the plasticity of the immune system and its capacity to be re-educated into a potent anti-tumor response. Thus, MDSCs within the TME became one of the major targets to improve the efficacy of tumor immunotherapy, and therapeutic strategies for tumor MDSCs were developed in the last few years. In the article, we analyzed the function of tumor MDSCs and the regulatory mechanisms of agents targeting MDSCs in tumor immunotherapy, and reviewed their therapeutic effects in MDSCs within the TME. Those data focused on discussing how to promote the differentiation and maturation of MDSCs, reduce the accumulation and expansion of MDSCs, and inhibit the function, migration and recruitment of MDSCs, further preventing the growth, invasion and metastasis of tumor. Those investigations may provide new directions for cancer therapy.
Copyright © 2021 Gao, Sui, Zhao, Gao, Su and Qu.

Entities:  

Keywords:  cancer; inhibitory factors; myeloid-derived suppressor cells; tumor immunotherapy; tumor microenvironment

Year:  2021        PMID: 33613512      PMCID: PMC7889583          DOI: 10.3389/fimmu.2020.585214

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  109 in total

Review 1.  Long non-coding RNA PVT1 and cancer.

Authors:  Ming Cui; Lei You; Xiaoxia Ren; Wenjing Zhao; Quan Liao; Yupei Zhao
Journal:  Biochem Biophys Res Commun       Date:  2016-02-03       Impact factor: 3.575

2.  COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.

Authors:  Victor Prima; Lyudmila N Kaliberova; Sergey Kaliberov; David T Curiel; Sergei Kusmartsev
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

3.  Lnc-C/EBPβ Negatively Regulates the Suppressive Function of Myeloid-Derived Suppressor Cells.

Authors:  Yunhuan Gao; Wei Sun; Wencong Shang; Yuanyuan Li; Dan Zhang; Tianze Wang; Xipeng Zhang; Shiwu Zhang; Yuan Zhang; Rongcun Yang
Journal:  Cancer Immunol Res       Date:  2018-08-31       Impact factor: 11.151

4.  Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.

Authors:  T Holtschke; J Löhler; Y Kanno; T Fehr; N Giese; F Rosenbauer; J Lou; K P Knobeloch; L Gabriele; J F Waring; M F Bachmann; R M Zinkernagel; H C Morse; K Ozato; I Horak
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

5.  Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.

Authors:  Li Wang; Isabelle Le Mercier; Juan Putra; Wenna Chen; Jun Liu; Austin D Schenk; Elizabeth C Nowak; Arief A Suriawinata; Jiannan Li; Randolph J Noelle
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

6.  Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer.

Authors:  Lifeng Li; Liping Wang; Jieyao Li; Zhirui Fan; Li Yang; Zhen Zhang; Chaoqi Zhang; Dongli Yue; Guohui Qin; Tengfei Zhang; Feng Li; Xinfeng Chen; Yu Ping; Dan Wang; Qun Gao; Qianyi He; Lan Huang; Hong Li; Jianmin Huang; Xuan Zhao; Wenhua Xue; Zhi Sun; Jingli Lu; Jane J Yu; Jie Zhao; Bin Zhang; Yi Zhang
Journal:  Cancer Res       Date:  2018-01-26       Impact factor: 12.701

7.  Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice.

Authors:  Yasushi Sawanobori; Satoshi Ueha; Makoto Kurachi; Takeshi Shimaoka; James E Talmadge; Jun Abe; Yusuke Shono; Masahiro Kitabatake; Kazuhiro Kakimi; Naofumi Mukaida; Kouji Matsushima
Journal:  Blood       Date:  2008-03-28       Impact factor: 22.113

8.  Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells.

Authors:  Evgeniy Eruslanov; Irina Daurkin; Javier Ortiz; Johannes Vieweg; Sergei Kusmartsev
Journal:  J Leukoc Biol       Date:  2010-06-29       Impact factor: 4.962

9.  VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

Authors:  J Louise Lines; Lorenzo F Sempere; Thomas Broughton; Li Wang; Randolph Noelle
Journal:  Cancer Immunol Res       Date:  2014-06       Impact factor: 11.151

10.  CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Authors:  Colin W Steele; Saadia A Karim; Joshua D G Leach; Peter Bailey; Rosanna Upstill-Goddard; Loveena Rishi; Mona Foth; Sheila Bryson; Karen McDaid; Zena Wilson; Catherine Eberlein; Juliana B Candido; Mairi Clarke; Colin Nixon; John Connelly; Nigel Jamieson; C Ross Carter; Frances Balkwill; David K Chang; T R Jeffry Evans; Douglas Strathdee; Andrew V Biankin; Robert J B Nibbs; Simon T Barry; Owen J Sansom; Jennifer P Morton
Journal:  Cancer Cell       Date:  2016-06-02       Impact factor: 38.585

View more
  10 in total

Review 1.  Crosstalk between angiogenesis and immune regulation in the tumor microenvironment.

Authors:  Hei Jung Kim; Young Rae Ji; You Mie Lee
Journal:  Arch Pharm Res       Date:  2022-06-27       Impact factor: 6.010

2.  Cancer Vaccination against Extracellular Vimentin Efficiently Adjuvanted with Montanide ISA 720/CpG.

Authors:  Karlijn van Loon; Elisabeth J M Huijbers; Jan David de Haan; Arjan W Griffioen
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

Review 3.  Myeloid-Derived Suppressor Cells in COVID-19: The Paradox of Good.

Authors:  Germana Grassi; Stefania Notari; Simona Gili; Veronica Bordoni; Rita Casetti; Eleonora Cimini; Eleonora Tartaglia; Davide Mariotti; Chiara Agrati; Alessandra Sacchi
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

Review 4.  Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies.

Authors:  Alejandro Olivares-Hernández; Luis Figuero-Pérez; Eduardo Terán-Brage; Álvaro López-Gutiérrez; Álvaro Tamayo Velasco; Rogelio González Sarmiento; Juan Jesús Cruz-Hernández; José Pablo Miramontes-González
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

Review 5.  Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade.

Authors:  Alecsandra Gorzo; Diana Galos; Simona Ruxandra Volovat; Cristian Virgil Lungulescu; Claudia Burz; Daniel Sur
Journal:  Life (Basel)       Date:  2022-02-02

Review 6.  Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End.

Authors:  Angeliki Datsi; Rüdiger V Sorg
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

Review 7.  Immunotherapy of targeting MDSCs in tumor microenvironment.

Authors:  Hongshu Sui; Shengyi Dongye; Xiaocui Liu; Xinghua Xu; Li Wang; Christopher Q Jin; Minhua Yao; Zhaoqing Gong; Daniel Jiang; Kexin Zhang; Yaling Liu; Hui Liu; Guomin Jiang; Yanping Su
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

Review 8.  Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Authors:  Dong-Rui Wang; Xian-Lin Wu; Ying-Li Sun
Journal:  Signal Transduct Target Ther       Date:  2022-09-19

Review 9.  The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.

Authors:  Zhigang Yi; Tao Ma; Jia Liu; Wenting Tie; Yanhong Li; Jun Bai; Lijuan Li; Liansheng Zhang
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

10.  Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity.

Authors:  Shunichi Taki; Kazuhide Sato; Kohei Matsuoka; Yuko Nishinaga; Kazuomi Takahashi; Hirotoshi Yasui; Chiaki Koike; Misae Shimizu; Mitsuo Sato
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 12.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.